2020
DOI: 10.1111/echo.14800
|View full text |Cite
|
Sign up to set email alerts
|

Focused echocardiography in cardio‐oncology

Abstract: Transthoracic echocardiography (TTE) is the cornerstone of imaging in patients with a malignancy in all stages of their treatment—before, during, and after the completion of it—to identify most of the cardiotoxic complications. However, the restricted time and resources of cardio‐oncology services and the high volume of oncological patients and survivors on the other hand limit the access of this population to this modality. Focused Echo in Cardio‐Oncology (FECO) in proportion to other focused cardiac protocol… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
6
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 36 publications
(40 reference statements)
0
6
0
Order By: Relevance
“…3D-TTE, 2D-TTE, CMR) is recommended throughout the entire treatment to decrease inter-technique variability. 94,199,200 Cardiac imaging should be performed at any time if patients receiving cardiotoxic therapies present with new cardiac symptoms.…”
Section: Cardiac Imagingmentioning
confidence: 99%
“…3D-TTE, 2D-TTE, CMR) is recommended throughout the entire treatment to decrease inter-technique variability. 94,199,200 Cardiac imaging should be performed at any time if patients receiving cardiotoxic therapies present with new cardiac symptoms.…”
Section: Cardiac Imagingmentioning
confidence: 99%
“…The role of CV imaging in cancer patients receiving cardiotoxic therapies has been highlighted in a position statement by the HFA 12 and in the European Society for Medical Oncology guidelines. 80 The role of focus echocardiography 81 and CMR 82 has also been recently discussed. In daily practice, caution should, however, be given if using late gadolinium enhancement or qualitative T2-weighted STIR imaging-only approach for the exclusion of checkpoint inhibitor-associated myocarditis.…”
Section: Hf In Cancer Patientsmentioning
confidence: 99%
“…For instance, docetaxel has been reported to affect 2.3-13% of the population, whereas the incidence of paclitaxel is less than 1%. 30 For cyclophosphamide, the incidence varies from 7-28% depending on its dose. 30,31 However, few studies have addressed the difference in protocols with the same chemotherapeutic agents.…”
Section: Discussionmentioning
confidence: 99%
“…30 For cyclophosphamide, the incidence varies from 7-28% depending on its dose. 30,31 However, few studies have addressed the difference in protocols with the same chemotherapeutic agents. In addition, no comparative studies have evaluated the cardiotoxicity of different agents in the same class.…”
Section: Discussionmentioning
confidence: 99%